Stock·NASDAQ·Technology
Astera Labs, Inc. (ALAB)
- Market cap
- $49.59B
- P/E
- 161.49
- Dividend yield
- 0.00%
- Street target
- $425.00median of 26 analysts
- 52-week range
- $97.89 $499.48
The short version
Where ALAB stands today, in four lines, and what CleaRank Financial AI makes of it.
ALAB at a glance
Astera Labs, Inc. (ALAB): Buy, 61/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 200-day but below its 50-day moving average ($249.81 and $315.33).
- Earnings ALAB beat estimates in 8 of its last 8 quarters, yet fell the next day after 5 of those beats.
- Insiders Insiders sold $1.2B and made no open-market purchases over the last 18 months.
- Valuation P/E of 161.5 against 35.1 for the Technology sector: a premium to peers (+360%).
Figures as of October 17, 2026.
CleaRank Financial AI
CleaRank rates Astera Labs, Inc. (ALAB) a Buy with a model score of 61/100.
The analysts' outlook adds the most to that score, with 18 of 26 analysts rating the stock a buy and a median target 48.7% above the price. Valuation pulls hardest in the other direction: the P/E of 161.49 is 360.1% above the sector median, a premium to peers, and the P/S of 43.59 is 473.6% above the sector median. The trend is mixed. ALAB sits 9.36% below its 50-day average of $315.33 but 14.41% above its 200-day average of $249.81. Across the past year, the price climbed 74.76%.
Only on CleaRank
Figures we compute ourselves from ALAB's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
2/4Price above its 50-day average ›
The price of $285.82 is 9.4% below the 50-day simple moving average of $315.33.Price above its 200-day average ›
The price is 14.4% above the 200-day simple moving average of $249.81.50-day average above the 200-day ›
The 50-day average ($315.33) is 26.2% above the 200-day average ($249.81), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 47% of its 52-week range, between $97.89 and $499.48.
ALAB share price
Pick a period: each tab shows how far ALAB has moved over it, to the last close.
Today's trading
Where ALAB sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
2/4P/E below the sector median ›
The trailing P/E of 161.49 is 360.1% above the Technology median of 35.1.P/S below the sector median ›
The price-to-sales ratio of 43.59 is 473.5% above the sector median of 7.6.Profitable over the last 12 months ›
Net income over the last 12 months was $369.5M on revenue of $1.2B, a net margin of 30.7%.Beat estimates in most recent reports ›
ALAB beat the EPS estimate in 8 of its last 8 reports.
Key statistics
The headline figures for ALAB.
As of October 17, 2026, ALAB trades at $285.82, with a market value of $49.59B and a P/E ratio of 161.49.
What the numbers say
CleaRank Financial AI's reading of ALAB's valuation, growth and risks.
Measured by earnings, ALAB trades at 161.49 times, compared with a Technology median of 35.1. That makes the P/E a premium to peers, sitting 360.1% above the median. On sales, the stock is priced at 43.59 times, which is 473.6% above the sector median of 7.6. To put its size in context, ALAB has a market capitalisation of $49.6B.
ALAB is growing its top line quickly. Revenue rose 104.50%, which is 80.3 percentage points faster than the sector median of 24.2%. Sales turn into profit at a net margin of 30.74% and an operating margin of 22.74%. Return on equity stands at 25.83%, above the sector median of 13.4%, and debt-to-equity of 0.03 points to a lightly indebted balance sheet.
ALAB's most recent quarterly report, dated August 4, 2026, showed EPS of $0.8. The figure topped the analysts' estimate by 15.94%. Despite the beat, the share price dropped 11.96% in the first session that followed the report.
The record is a clean sweep: 8 beats in 8 reports, but beats have not guaranteed gains: the stock fell the next day after 5 of them. The largest of the earlier reactions came after the February 10, 2026 report, which beat the estimate by 13.73% while the stock fell 21.41%.
Day-to-day volatility is the first thing to plan around: ALAB has moved 5.48% on an average session. The P/E of 161.49, 360.1% above the sector median, puts ALAB at a premium to peers, so weaker results would meet a higher bar. The price is 42.78% below its 52-week high of $499.48. Insiders sold $1.2B over the last 18 months and bought none on the open market, though sales of this kind are often planned in advance and say less than purchases would.
ALAB against the Technology sector
How ALAB compares with the median Technology stock CleaRank tracks.
Price to earnings vs sector: ALAB trades at a significant premium to sector peers (+360%), suggesting market expectations for superior growth or market position.
Return vs XLK: Since May 6, 2025, ALAB has gained 300.5% against a gain of 71.7% for XLK.
Performance against XLK
ALAB and the Technology sector fund over the same days.
Revenue and earnings
How much ALAB sells, and how much of it becomes profit.
Revenue growth: Revenue grew 115.1% in FY2025 to $853M, from $396M a year earlier.
Profit margin: The net margin was 25.7% in FY2025, up from -21.1% the year before.
Profitable: ALAB earned $219M in FY2025.
Earnings reality check
Did ALAB beat what analysts expected, and how did the stock react?
Earnings record: ALAB beat the analyst estimate in 8 of the last 8 quarters.
Market reaction: The stock fell in the first session after 5 of those 8 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 4, 2026after close | $0.69 | $0.80 | +15.94% | -11.96% | -13.74% |
| May 5, 2026after close | $0.54 | $0.61 | +12.96% | -0.83% | -5.23% |
| Feb 10, 2026after close | $0.51 | $0.58 | +13.73% | -21.41% | -29.14% |
| Nov 4, 2025after close | $0.39 | $0.49 | +25.64% | +1.47% | -6.56% |
| Aug 5, 2025after close | $0.32 | $0.44 | +37.50% | +28.66% | +41.66% |
| May 6, 2025after close | $0.28 | $0.33 | +17.86% | -0.38% | +22.98% |
| Feb 10, 2025after close | $0.26 | $0.37 | +42.31% | -10.89% | -9.70% |
| Nov 4, 2024after close | $0.17 | $0.23 | +35.29% | +37.70% | +32.45% |
As of October 17, 2026, ALAB has beaten the analyst EPS estimate in 8 of its last 8 reported quarters and fell in the first trading session after 5 of those beats; its latest report, on August 4, 2026, came in 15.94% above the estimate and the stock moved -11.96% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 37.4, showing bearish momentum without being oversold.RSI above 50 ›
An RSI of 37.4 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of ALAB
The score, the reasoning behind it, and what could move the price next.
Astera Labs, Inc. (ALAB) shows a mixed trend. At $285.82, the stock is 9.36% below its 50-day average of $315.33, yet 14.41% above its 200-day average of $249.81. The 50-day average is 26.23% above the 200-day, but the price has already slipped beneath the shorter average. Across its 52-week range of $97.89 to $499.48, the price stands at 47%, and it is 42.78% below the high.
The 14-day RSI of 37.4 is in the bearish zone, above the oversold line, and the MACD line is negative. The short and long run point different ways: the price rose 6.18% over the past month, fell 5.86% over the past three months and rose 74.76% over the past year.
Analyst upgrade ›
Northland Capital Markets upgraded it to Outperform from Market Perform on August 17, 2026.
Source: Analyst action, Northland Capital Markets, August 17, 2026
Earnings beat ›
The August 4, 2026 report beat the EPS estimate by 15.94%, and the share price fell 11.96% in the first session after it.
Source: Earnings report, August 4, 2026
- The two levels closest to the price matter most: the 50-day SMA at $315.33 sits above it, and the 200-day SMA at $249.81 sits below.
- The 14-day RSI reads 37.4, in the bearish zone, with the MACD line negative; readings above 70 or below 30 mark stretched momentum.
- The share price dropped 11.96% in the first session after the August 4, 2026 report, even though ALAB has beaten estimates in 8 of the last 8 reports.
ALAB's trend signals point in opposite directions. The price sits above its 200-day average of $249.81 but below its 50-day average of $315.33. Closing above the 50-day would flip both signals to upward, while closing below the 200-day would flip both to downward. Going up, the first hurdle is the 50-day SMA at $315.33; going down, the first floor is the 200-day SMA at $249.81.
Technical indicators
Momentum and trend for ALAB, from its daily closes.
As of October 17, 2026, with ALAB at $285.82, its 14-day RSI is 37.4 (showing bearish momentum without being oversold), its 50-day simple moving average is $315.33 and its 200-day is $249.81.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What ALAB moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, ALAB's 1-year correlation of daily returns is +0.47 with S&P 500 (SPY), +0.57 with Nasdaq 100 (QQQ), +0.24 with Bitcoin (BTC) and +0.10 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
18 of 26 analysts rate it a buy or strong buy, 8 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $425.00 is 48.7% above the price.More buy ratings than three months ago ›
18 of 26 rate it a buy now, against 18 of 26 three months ago.
ALAB Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 17, 2026 | Northland Capital Markets | Upgrade | Outperform |
| Aug 5, 2026 | TD Cowen | Maintains | Hold |
| Aug 5, 2026 | Morgan Stanley | Maintains | Overweight |
| Aug 5, 2026 | RBC Capital | Maintains | Outperform |
| Aug 5, 2026 | Evercore ISI Group | Maintains | Outperform |
| Aug 5, 2026 | Needham | Maintains | Buy |
As of October 17, 2026, 26 Wall Street analysts cover ALAB: 18 rate it a buy or strong buy, 8 a hold and 0 a sell or strong sell. Their 12-month price targets range from $190.00 to $500.00, with a median of $425.00, 48.7% above the price of $285.82.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
ALAB trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
ALAB moves about 5.5% a day on average, so a stop can fill well past its level. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much ALAB tends to move, against the market and on its own.
The long record
ALAB's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/3Average daily move under 2% ›
The price has moved 5.48% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 63.7%, from December 2024 to April 2025, regained by August 2025.Beat the S&P 500 since the chart begins ›
$10,000 invested in March 2024 is now worth $46,078, against $15,096 in the S&P 500 (SPY).
ALAB Drawdowns & Recovery
As of October 17, 2026, ALAB's worst peak-to-trough fall over the last 3 years with dividends reinvested was -63.7% (December 2024 to April 2025); it regained that peak by August 2025, 4 months after the low.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into ALAB in March 2024 is worth now, against the same amount in the S&P 500.
Against the market: ALAB beat the S&P 500 over this period: $46,078 against $15,096.
A $10,000 investment in ALAB in March 2024 would be worth about $46,078 today with dividends reinvested, compared with about $15,096 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to ALAB, and which have not.
Strongest month, April: an average of +35.88%.
Weakest month, February: an average of -23.14%.
This month, October: has averaged +17.21%. Past seasonality does not repeat on schedule.
Average return for each calendar month over the stored price history; treat short histories with caution.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in ALAB, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in ALAB today could grow to about $29,886 by 2036 in the base case, with a 90th-percentile outcome near $226,734 and a 10th-percentile outcome around $3,939. Projections are statistical simulations, not guarantees.
ALAB Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $443 for ALAB by 2030 in the base case, from $286 today (1.5x over 4 years). The 10th-percentile path ends near $123. These are outcomes of a Monte Carlo simulation run on ALAB's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $168 | $319 | $605 | |
| 2028 | $144 | $356 | $881 | |
| 2029 | $131 | $397 | $1,204 | |
| 2030 | $123 | $443 | $1,595 | |
| 2031 | $118 | $494 | $2,071 |
Method: a lognormal simulation of ALAB's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. ALAB is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation.
Insider trading
What the people running the company have bought and sold.
ALAB insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought ALAB shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 17, 2026, ALAB insiders reported 84 open-market sales worth $1.2B and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Craig H Barratt
Director
|
Grant | 68 | $21.2K |
| Oct 1, 2026 | Michael E. Hurlston
Director
|
Grant | 72 | $22.4K |
| Sep 2, 2026 | Stefan A Dyckerhoff
Director
|
Sell | 12.5K | $3.4M |
| Sep 1, 2026 | Manuel Alba
Director
|
Sell | 183.0K | $51.3M |
| Aug 17, 2026 | Sanjay Gajendra
President
|
Sell | 90.6K | $30.8M |
| Aug 17, 2026 | Jitendra Mohan
Chief Executive Officer
|
Sell | 90.6K | $30.8M |
| Aug 17, 2026 | Philip Mazzara
General Counsel
|
Sell | 6.8K | $2.3M |
| Aug 6, 2026 | Stefan A Dyckerhoff
Director
|
Sell | 12.5K | $3.9M |
| Jul 20, 2026 | Germaine Cota
Officer
|
Grant | 1.5K | - |
| Jul 1, 2026 | Manuel Alba
Director
|
Sell | 137.0K | $60.5M |
| Jul 1, 2026 | Manuel Alba
Director
|
Sell | 37.5K | $16.8M |
| Jul 1, 2026 | Stefan A Dyckerhoff
Director
|
Sell | 12.5K | $5.6M |
| Jul 1, 2026 | Manuel Alba
Director
|
Sell | 8.5K | $3.9M |
| Jun 24, 2026 | Bethany J Mayer
Director
|
Sell | 686 | $271.0K |
| Jun 4, 2026 | Jack R Lazar
Director
|
Sell | 10.0K | $3.6M |
| Jun 4, 2026 | Craig H Barratt
Director
|
Grant | 837 | - |
| Jun 4, 2026 | Stefan A Dyckerhoff
Director
|
Grant | 837 | - |
| Jun 4, 2026 | Michael E. Hurlston
Director
|
Grant | 837 | - |
| Jun 4, 2026 | Jack R Lazar
Director
|
Grant | 837 | - |
| Jun 4, 2026 | Bethany J Mayer
Director
|
Grant | 837 | - |
| Jun 3, 2026 | Stefan A Dyckerhoff
Director
|
Sell | 12.5K | $4.6M |
| May 22, 2026 | Sanjay Gajendra
President
|
Grant | 226.2K | - |
| May 21, 2026 | Sanjay Gajendra
President
|
Sell | 400.0K | $116.1M |
| May 21, 2026 | Philip Mazzara
General Counsel
|
Sell | 796 | $231.7K |
| May 19, 2026 | Sanjay Gajendra
President
|
Sell | 280.0K | $69.8M |
| May 19, 2026 | Jitendra Mohan
Chief Executive Officer
|
Sell | 140.0K | $31.3M |
| May 18, 2026 | Sanjay Gajendra
President
|
Sell | 95.4K | $21.5M |
| May 18, 2026 | Jitendra Mohan
Chief Executive Officer
|
Sell | 95.4K | $21.5M |
| May 18, 2026 | Philip Mazzara
General Counsel
|
Sell | 14.1K | $3.3M |
| May 14, 2026 | Philip Mazzara
General Counsel
|
Grant | 131 | $30.0K |
| May 7, 2026 | Sanjay Gajendra
President
|
Sell | 230.6K | $45.7M |
| May 7, 2026 | Jitendra Mohan
Chief Executive Officer
|
Sell | 140.0K | $28.0M |
| May 7, 2026 | Sanjay Gajendra
President
|
Sell | 40.3K | $8.0M |
| May 7, 2026 | Stefan A Dyckerhoff
Director
|
Sell | 12.5K | $2.5M |
| May 1, 2026 | Desmond M Lynch
Chief Financial Officer
|
Grant | 49.6K | - |
| Apr 20, 2026 | Jitendra Mohan
Chief Executive Officer
|
Sell | 335.9K | $57.9M |
| Apr 20, 2026 | Stefan A Dyckerhoff
Director
|
Sell | 25.0K | $4.4M |
| Apr 15, 2026 | Jitendra Mohan
Chief Executive Officer
|
Sell | 3.0K | $518.0K |
| Apr 10, 2026 | Jitendra Mohan
Chief Executive Officer
|
Sell | 123.8K | $18.5M |
| Apr 1, 2026 | Manuel Alba
Director
|
Sell | 183.0K | $19.7M |
| Apr 1, 2026 | Philip Mazzara
General Counsel
|
Sell | 10.0K | $1.1M |
| Mar 17, 2026 | Jitendra Mohan
Chief Executive Officer
|
Sell | 157.5K | $20.7M |
| Mar 16, 2026 | Jack R Lazar
Director
|
Sell | 2.5K | $325.0K |
| Mar 5, 2026 | Jack R Lazar
Director
|
Sell | 7.5K | $898.5K |
| Mar 2, 2026 | Philip Mazzara
General Counsel
|
Sell | 10.0K | $1.2M |
| Feb 17, 2026 | Sanjay Gajendra
President
|
Sell | 95.0K | $11.8M |
| Feb 17, 2026 | Jitendra Mohan
Chief Executive Officer
|
Sell | 95.0K | $11.8M |
| Feb 17, 2026 | Michael Truett Tate
Chief Financial Officer
|
Sell | 12.0K | $1.5M |
| Feb 17, 2026 | Philip Mazzara
General Counsel
|
Sell | 4.8K | $600.3K |
| Feb 6, 2026 | Sanjay Gajendra
President
|
Grant | 26.5K | - |
| Feb 6, 2026 | Philip Mazzara
General Counsel
|
Grant | 5.9K | - |
| Feb 6, 2026 | Jitendra Mohan
Chief Executive Officer
|
Grant | 26.5K | - |
| Feb 6, 2026 | Michael Truett Tate
Chief Financial Officer
|
Grant | 11.8K | - |
| Feb 2, 2026 | Germaine Cota
Officer
|
Grant | 24.9K | - |
| Jan 2, 2026 | Philip Mazzara
General Counsel
|
Sell | 10.0K | $1.8M |
| Dec 2, 2025 | Sanjay Gajendra
President
|
Grant | 142.0K | - |
| Dec 1, 2025 | Manuel Alba
Director
|
Sell | 150.0K | $24.9M |
| Dec 1, 2025 | Manuel Alba
Director
|
Sell | 33.0K | $5.5M |
| Dec 1, 2025 | Jitendra Mohan
Chief Executive Officer
|
Grant | 559.2K | - |
| Nov 20, 2025 | Jack R Lazar
Director
|
Sell | 2.5K | $373.9K |
| Nov 17, 2025 | Sanjay Gajendra
President
|
Sell | 90.5K | $13.1M |
| Nov 17, 2025 | Jitendra Mohan
Chief Executive Officer
|
Sell | 90.5K | $13.1M |
| Nov 17, 2025 | Michael Truett Tate
Chief Financial Officer
|
Sell | 11.4K | $1.7M |
| Nov 17, 2025 | Philip Mazzara
General Counsel
|
Sell | 4.6K | $668.5K |
| Nov 14, 2025 | Philip Mazzara
General Counsel
|
Grant | 87 | $12.6K |
| Oct 1, 2025 | Philip Mazzara
General Counsel
|
Sell | 10.0K | $1.9M |
| Sep 11, 2025 | Michael Truett Tate
Chief Financial Officer
|
Grant | 7.0K | - |
| Sep 2, 2025 | Manuel Alba
Director
|
Sell | 183.0K | $31.7M |
| Sep 2, 2025 | Sanjay Gajendra
President
|
Grant | 480.7K | - |
| Aug 28, 2025 | Philip Mazzara
General Counsel
|
Sell | 10.0K | $1.9M |
| Aug 27, 2025 | Jack R Lazar
Director
|
Sell | 22.5K | $4.0M |
| Aug 20, 2025 | Jitendra Mohan
Chief Executive Officer
|
Grant | 150.0K | - |
| Aug 19, 2025 | Michael Truett Tate
Chief Financial Officer
|
Grant | 55.8K | - |
| Aug 18, 2025 | Sanjay Gajendra
President
|
Sell | 91.4K | $16.8M |
| Aug 18, 2025 | Jitendra Mohan
Chief Executive Officer
|
Sell | 91.4K | $16.8M |
| Aug 18, 2025 | Michael Truett Tate
Chief Financial Officer
|
Sell | 18.9K | $3.5M |
| Aug 18, 2025 | Philip Mazzara
General Counsel
|
Sell | 7.2K | $1.3M |
| Aug 13, 2025 | Stefan A Dyckerhoff
Director
|
Grant | 11.0K | - |
| Aug 12, 2025 | Michael Truett Tate
Chief Financial Officer
|
Sell | 100.0K | $19.1M |
| Aug 8, 2025 | Stefan A Dyckerhoff
Director
|
Sell | 52.0K | $9.1M |
| Aug 8, 2025 | Michael Truett Tate
Chief Financial Officer
|
Grant | 17.5K | - |
| Aug 7, 2025 | Sanjay Gajendra
President
|
Sell | 280.0K | $47.6M |
| Aug 7, 2025 | Jitendra Mohan
Chief Executive Officer
|
Sell | 152.5K | $26.0M |
| Aug 7, 2025 | Michael Truett Tate
Chief Financial Officer
|
Sell | 100.0K | $17.1M |
| Jul 24, 2025 | Philip Mazzara
General Counsel
|
Grant | 16.2K | - |
| Jul 24, 2025 | Michael Truett Tate
Chief Financial Officer
|
Grant | 43.2K | - |
| Jul 21, 2025 | Jitendra Mohan
Chief Executive Officer
|
Sell | 76.3K | $8.6M |
| Jul 21, 2025 | Manuel Alba
Director
|
Sell | 13.3K | $1.5M |
| Jul 18, 2025 | Jitendra Mohan
Chief Executive Officer
|
Sell | 126.3K | $12.2M |
| Jul 10, 2025 | Jitendra Mohan
Chief Executive Officer
|
Sell | 18.3K | $1.9M |
| Jul 9, 2025 | Sanjay Gajendra
President
|
Sell | 165.0K | $16.3M |
| Jul 3, 2025 | Manuel Alba
Director
|
Sell | 94.0K | $8.5M |
| Jun 26, 2025 | Bethany J Mayer
Director
|
Grant | 839 | - |
| Jun 24, 2025 | Bethany J Mayer
Director
|
Sell | 686 | $60.0K |
| Jun 20, 2025 | Jitendra Mohan
Chief Executive Officer
|
Sell | 52.7K | $5.3M |
| Jun 20, 2025 | Manuel Alba
Director
|
Sell | 20.2K | $2.0M |
| Jun 18, 2025 | Sanjay Gajendra
President
|
Sell | 76.4K | $7.5M |
| Jun 17, 2025 | Jitendra Mohan
Chief Executive Officer
|
Sell | 106.5K | $10.1M |
| Jun 6, 2025 | Manuel Alba
Director
|
Grant | 2.4K | - |
| Jun 6, 2025 | Craig H Barratt
Director
|
Grant | 2.4K | - |
| Jun 6, 2025 | Stefan A Dyckerhoff
Director
|
Grant | 2.4K | - |
| Jun 6, 2025 | Michael E. Hurlston
Director
|
Grant | 2.4K | - |
| Jun 6, 2025 | Jack R Lazar
Director
|
Grant | 2.4K | - |
| Jun 6, 2025 | Bethany J Mayer
Director
|
Grant | 2.4K | - |
| Jun 4, 2025 | Sanjay Gajendra
President
|
Sell | 88.6K | $8.7M |
| May 30, 2025 | Michael Truett Tate
Chief Financial Officer
|
Sell | 500.0K | $45.1M |
| May 29, 2025 | Jitendra Mohan
Chief Executive Officer
|
Sell | 14.2K | $1.4M |
| May 29, 2025 | Manuel Alba
Director
|
Sell | 600 | $60.0K |
| May 27, 2025 | Sanjay Gajendra
President
|
Sell | 165.0K | $16.2M |
| May 19, 2025 | Jitendra Mohan
Chief Executive Officer
|
Sell | 128.3K | $11.5M |
| May 19, 2025 | Philip Mazzara
General Counsel
|
Sell | 28.8K | $2.6M |
| May 16, 2025 | Sanjay Gajendra
President
|
Sell | 91.3K | $8.3M |
| May 16, 2025 | Jitendra Mohan
Chief Executive Officer
|
Sell | 91.3K | $8.3M |
| May 16, 2025 | Michael Truett Tate
Chief Financial Officer
|
Sell | 9.1K | $825.7K |
| May 15, 2025 | Michael E. Hurlston
Director
|
Sell | 2.5K | $228.9K |
| May 14, 2025 | Jitendra Mohan
Chief Executive Officer
|
Sell | 75.0K | $6.8M |
| May 14, 2025 | Philip Mazzara
General Counsel
|
Grant | 196 | $14.4K |
| May 8, 2025 | Sanjay Gajendra
President
|
Sell | 165.0K | $11.8M |
| May 8, 2025 | Jitendra Mohan
Chief Executive Officer
|
Sell | 75.0K | $5.3M |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.